Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Hot Flushes, Menopause, Postmenopause
Interventions: Esterified Estrogens (EE) and Methyltestosterone (MT); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 1,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 88
States / cities: Montgomery, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 69 more

Conditions: Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions: [203Pb]VMT01, [212Pb]VMT01, Nivolumab; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 16
States / cities: Orange, California • Jacksonville, Florida • Miami, Florida + 12 more

Conditions: Varicose Veins, Venous Insufficiency
Interventions: VNUS RF ClosureFAST, VenaCure EVLT NeverTouch; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 6
States / cities: Sacramento, California • Bradenton, Florida • Melrose Park, Illinois + 3 more

Conditions: Hypertension, Pulmonary, Ventricular Dysfunction, Left
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • Torrance, California + 11 more

Conditions: Delayed Healing
Interventions: PICO; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois • The Bronx, New York • Cleveland, Ohio

Conditions: Mild Cognitive Impairment, Memory Disorders, Mild Dementia, Impaired Cognition, Mild Cognitive Disorder, Amnestic Disorder, Dementia and Amnestic Conditions, Poor Short-term Memory, Memory Impairment
Interventions: Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group (patient and partner), Wellness Education, Physical Exercise; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Diabetic Polyneuropathy
Interventions: Thioctic Acid, Placebo; Drug
Lead sponsor: MEDA Pharma GmbH & Co. KG; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2005
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 21 more

Conditions: Acromegaly
Interventions: Lanreotide (Autogel formulation); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Source MDx; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 17
States / cities: San Bernardino, California • Denver, Colorado • Chicago, Illinois + 11 more

Conditions: Asthma
Interventions: Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Chula Vista, California • Fresno, California + 29 more

Conditions: Stargardt's Macular Dystrophy
Interventions: MA09-hRPE; Biological
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Diabetic Foot Ulcer
Interventions: PriMatrix Dermal Repair Scaffold, Secondary Dressings, Offloading device; Device
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 17
States / cities: Carlsbad, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Opioid Dependence, on Agonist Therapy
Interventions: Higher bioavailability BNX sublingual tablets; Drug
Lead sponsor: Orexo AB; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 28
States / cities: Jefferson County, Alabama • Marion County, Alabama • Winston County, Alabama + 25 more

Conditions: Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions: GS-9219; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 5
States / cities: San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Healthy Study Participants
Interventions: glovadalen, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Glendale, California

Conditions: Colorectal Cancer, Benign or Malignant Rectal or Colon Tumors
Interventions: Robotic Assisted Surgery; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 7
States / cities: Orlando, Florida • Detroit, Michigan • Rochester, Minnesota + 4 more

Conditions: Bladder Cancer
Interventions: TAR-200, Cetrelimab, BCG Vesiculture; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 51
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Long Beach, California + 42 more

Conditions: Breast Cancer
Interventions: [68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more

Conditions: Multiple Myeloma
Interventions: Panobinostat, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Ajai Chari; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Angelman Syndrome
Interventions: obudanersen; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Carrboro, North Carolina

Conditions: Schizophrenia
Interventions: ITI-007, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 8 more

Conditions: Major Depressive Disorder
Interventions: sertraline, venlafaxine XR; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Acne Vulgaris
Interventions: Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Hawthorne, New York

Conditions: Venous Leg Ulcer
Interventions: Dermagraft, Profore; Device
Lead sponsor: Shire Regenerative Medicine, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Phoenix, Arizona • Fresno, California • Mather, California + 8 more

Search by objective public record fields.

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Comparison Study for Safety and Efficacy of Two Devices for the Treatment of the Great Saphenous Vein

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction

PICO Breast Reduction Clinical Study Looking at Incision Healing Complications

Behavioral Interventions to Prevent or Delay Dementia

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

PRostate Cancer Individual Signature Evaluation Trial in Patients Undergoing Scheduled Prostate Biopsy

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

PriMatrix for the Management of Diabetic Foot Ulcers

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)

A Trial to Assess the Antipsychotic Efficacy of ITI-007

Sertraline vs. Venlafaxine XR

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers